September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
The Idiopathic Intracranial Hypertension Treatment Trial: Outcomes from Months 6 - 12
Author Affiliations & Notes
  • Michael Wall
    Univ of Iowa, Carver Coll of Med, Iowa City, Iowa, United States
  • Mark J Kupersmith
    Ophthalmology, Icahn School of Medicine at Mount Sinai , New York, New York, United States
    Ophthalmology, Roosevelt Hospital, New York City, New York, United States
  • Elizabeth-Ann Moss
    Ophthalmology, Roosevelt Hospital, New York City, New York, United States
  • Peggy Auinger
    Center for Human Experimental Therapeutics, University of Rochester, Rochester, New York, United States
  • Footnotes
    Commercial Relationships   Michael Wall, None; Mark Kupersmith, None; Elizabeth-Ann Moss, None; Peggy Auinger, None
  • Footnotes
    Support  NORDIC 1U10EY017281-01A1
Investigative Ophthalmology & Visual Science September 2016, Vol.57, No Pagination Specified. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michael Wall, Mark J Kupersmith, Elizabeth-Ann Moss, Peggy Auinger; The Idiopathic Intracranial Hypertension Treatment Trial: Outcomes from Months 6 - 12. Invest. Ophthalmol. Vis. Sci. 201657(12):.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To determine whether the beneficial effects of acetazolamide (ACZ) in improving vision continues from months 6 to 12 in participants of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT)

Methods : In the IIHTT, after 6 months of a weight management program and either placebo or maximally tolerated ACZ, subjects transitioned from study drug to ACZ unless their papilledema had resolved. The main outcome was the change in mean deviation (MD) from Month 6 to Month 12 in the study eye of groups based on treatment at study entry and after 6 mos.: 1) ACZ to ACZ; n = 34, 2) placebo to ACZ; n = 35, 3) ACZ to no treatment; n = 20, and 4) placebo to no treatment; n = 12. No treatment with ACZ was given if papilledema had resolved.

Results : The placebo subjects in group 4 with no ACZ treatment improved 0.86 dB MD units at 12 mos, p = 0.04. The other three groups improved 0.35 to 0.41 dB MD. Mean improvements in papilledema grade also occurred in all groups but most markedly in the group that exchanged placebo for ACZ (0.94 Frisén grade units, p < 0.001). Quality of life scores and headache disability, also improved with the largest and significant improvement in the group that transitioned from placebo to ACZ. Significant weight change occurred in those transitioning from placebo to ACZ who lost about 6 pounds (p = 0.02) while those tapered off ACZ gained about 6 pounds (p = 0.03).

Conclusions : Clinical improvements in MD continued from month 6 to month 12 of the IIHTT in all treatment groups. This effect was most marked and significant in the placebo group with no papilledema tapered off study drug. Significantly beneficial effects of ACZ on papilledema grade and QoL increased from month 6 to 12. Adding ACZ to the placebo group subjects significantly improved their quality of life measures.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×